IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
History of Changes and the ClinicalTrials.gov Archive Site
Information in a ClinicalTrials.gov record can be modified at any time by the data provider.
The display at ClinicalTrials.gov shows the most recent version for each data element.
The date first received and the date last updated are listed at the top of each record.
The full history of changes since the record was first received is available in the
archival version of the record on the ClinicalTrials.gov Archive Site.
Current Study:
The display at ClinicalTrials.gov shows the most recent version for each data element.
The date first received and the date last updated are listed at the top of each record.
The full history of changes since the record was first received is available in the
archival version of the record on the ClinicalTrials.gov Archive Site.
Current Study:
| ClinicalTrials.gov Identifier: | NCT02484404 |
|---|---|
| Study Title: | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers |
| First Received: | June 25, 2015 |
| Last Updated: | July 12, 2017 |
Continue to the history of changes for this study on the